ADMA Biologics (NASDAQ:ADMA) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded ADMA Biologics from a "buy" to a "hold" rating in a report issued Monday.
• Analyst views are mixed—two analysts rate ADMA a Strong Buy, one a Buy and three Hold, leaving a consensus rating of "Moderate Buy" with a $25.67 average price target.
• Shares opened at $10.52 (12‑month range $7.21–$24.17) after ADMA reported Q4 EPS of $0.20 (in line) and revenue of $139.16M (+18.4% YoY); the company has a $2.51B market cap, a PE of 17.5 and analysts project ~0.93 EPS for the year.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Monday.

A number of other equities research analysts also recently weighed in on ADMA. Canaccord Genuity Group assumed coverage on shares of ADMA Biologics in a research note on Monday, April 20th. They set a "buy" rating and a $21.00 price target on the stock. Cantor Fitzgerald reiterated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research downgraded shares of ADMA Biologics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 27th. Finally, Mizuho decreased their price target on shares of ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating on the stock in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $25.67.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $10.52 on Monday. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $24.17. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The business's 50 day moving average is $12.50 and its two-hundred day moving average is $15.58. The company has a market cap of $2.51 billion, a PE ratio of 17.53 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. ADMA Biologics's quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the company posted $0.46 earnings per share. Equities analysts predict that ADMA Biologics will post 0.93 EPS for the current year.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms purchased 7,000 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.90% of the company's stock.

Institutional Trading of ADMA Biologics

Several large investors have recently modified their holdings of ADMA. Fifth Third Bancorp lifted its position in shares of ADMA Biologics by 7,773.5% during the 1st quarter. Fifth Third Bancorp now owns 55,508 shares of the biotechnology company's stock worth $500,000 after buying an additional 54,803 shares during the last quarter. PFG Investments LLC lifted its position in shares of ADMA Biologics by 4.1% during the 1st quarter. PFG Investments LLC now owns 222,729 shares of the biotechnology company's stock worth $2,007,000 after buying an additional 8,728 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company's stock worth $9,690,000 after buying an additional 1,008,548 shares during the last quarter. Peregrine Capital Management LLC lifted its position in shares of ADMA Biologics by 29.8% during the 1st quarter. Peregrine Capital Management LLC now owns 611,826 shares of the biotechnology company's stock worth $5,513,000 after buying an additional 140,370 shares during the last quarter. Finally, Inspire Investing LLC lifted its position in shares of ADMA Biologics by 119.7% during the 1st quarter. Inspire Investing LLC now owns 56,398 shares of the biotechnology company's stock worth $508,000 after buying an additional 30,722 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.